Developer docs
API playgroundTry for free, no card

Search company profiles

Ray Therapeutics

Full company profile

uuid0000odq

Namestring
Ray Therapeutics
Legal namestring
Ray Therapeutics, Inc.
Company typeenum
Private
Founded yearint
2021
Descriptiontext

Ray Therapeutics is a clinical-stage biotechnology company founded in 2021 that develops optogenetic gene therapies intended to restore vision in patients with advanced, blinding retinal diseases. The company's core technology is a proprietary platform that uses bioengineered, highly light-sensitive channelrhodopsin proteins — notably ChRown — delivered via AAV-based gene therapy to reprogram surviving retinal neurons (ganglion cells or ON-bipolar cells, depending on the program) into functional photosensors that transmit visual signals to the brain. Because the approach is mutation-agnostic, it can in principle address retinitis pigmentosa, choroideremia, Stargardt disease, and geographic atrophy secondary to AMD through a single intravitreal injection intended as a one-time, lifelong treatment that does not require light-enhancing eyewear.

The pipeline is currently materialized in two named clinical-stage candidates: RTx-015 (lead), which targets retinal ganglion cells and is being evaluated in the ENVISION Phase 1 trial (NCT06460844) for retinitis pigmentosa and choroideremia, having received both FDA Regenerative Medicine Advanced Therapy (RMAT) designation and European Medicines Agency Priority Medicines (PRIME) designation in April 2026; and RTx-021, which targets retinal ON-bipolar cells and is being advanced for Stargardt disease and geographic atrophy (secondary to AMD).

Ray Therapeutics is pre-revenue and funds its operations through a syndicate of life-sciences venture and crossover investors and California Institute for Regenerative Medicine (CIRM) grants. Cumulative capital raised to date includes a $6M seed (2022, 4BIO Capital), a $100M Series A (2023, Novo Holdings A/S lead), a $125M Series B (2026, Janus Henderson Investors lead), and CIRM grants of $4M (2022), $4M (2023) and $8M (2025). Manufacturing is enabled through a CDMO partnership with Forge Biologics for AAV process development, scale-up, cGMP manufacturing, and plasmid DNA production. The expected go-to-market is a specialty ophthalmology commercial model leveraging one-time gene-therapy pricing typical of rare-disease retinal therapeutics, with U.S. as primary market and Europe signaled via the PRIME designation.

Short descriptiontext

Ray Therapeutics is a clinical-stage biotechnology company developing bioengineered optogenetic gene therapies delivered via a single intravitreal injection to restore vision in patients with blinding retinal diseases such as retinitis pigmentosa and choroideremia.

Operating statusenum
Operating
Ownership categoryenum
Headcount rangeband
51–100
akta.pro rankint
HeadquartersBerkeley, United States
HQ citystring
Berkeley
HQ countrystring
United States
HQ regionstring
North America
Markets served

Serves global market

Keyword5 values
optogenetic gene therapy, retinal disease therapy, AAV gene therapy, ophthalmic biotechnology, inherited retinal diseases
Industry3 codes
PRIMARYHLAAACAG
Ophthalmology Gene Therapies
Healthcare & Life Sciences/Biotechnology & Biologics/Gene Therapy (AAV/lentiviral/other vectors)
SECONDARYHLAAACAE
Gene Therapy for Rare/Monogenic Diseases
Healthcare & Life Sciences/Biotechnology & Biologics/Gene Therapy (AAV/lentiviral/other vectors)
SECONDARYHLAIAIAK
Rare Ophthalmology Disorder Therapies
Healthcare & Life Sciences/Pharmaceuticals/Orphan & Rare Disease Pharmaceuticals
NAICS code1 code
  • Research and Development in Biotechnology (except Nanobiotechnology)541714
SIC code1 code
  • Biological Products, (No Disgnostic Substances)2836
Product category
Ophthalmic Gene Therapy Biopharmaceuticals
Social media profiles1 record
GTM motion3 records

Each record includes

Type, Description, Source

Revenue model3 records
1Pre-revenue clinical-stage gene therapy
TypeOne Time License
Description

Ray Therapeutics is a clinical-stage biopharmaceutical company with no commercial product revenue; future revenue model is expected to be one-time gene therapy treatments administered via single intravitreal injection (a unit-pricing/one-time-payment biotech model) delivered to patients with advanced retinal degeneration.

raytherapeutics.com
2Non-dilutive grant funding (CIRM)
TypeManaged Services
Description

Receives milestone-based grant funding from the California Institute for Regenerative Medicine (CIRM) — including a $4M grant (CLIN2-17086) and an $8M award — supporting clinical development of optogenetic programs.

raytherapeutics.com
3Private equity financing
TypeTransaction Fee
Description

Capital raised via priced equity rounds: $6M seed (2022), $100M Series A (2023), $125M Series B (2026) from a syndicate of life-sciences venture and crossover investors.

raytherapeutics.com
Cost components5 values
Technology or R&D, Personnel, Operations, Marketing or Sales, Supply Chain
GTM typeB2B
B2B
Offering typeHardware or Manufacturing
Hardware or Manufacturing
Brand1 of 3 records shown
1RTx-015
Description

Lead optogenetic gene therapy candidate of Ray Therapeutics, administered as a single intravitreal injection and being evaluated in a Phase 1 clinical trial (ENVISION) for retinitis pigmentosa and choroideremia; granted FDA RMAT designation (April 2026) and EMA PRIME designation (April 2026).

raytherapeutics.com
+2 more records
Core offering1 text field

Ray Therapeutics is a clinical-stage biopharmaceutical company developing bioengineered optogenetic gene therapies that use light-sensitive channelrhodopsin proteins delivered via AAV-based gene therapy to reprogram surviving retinal neurons, restoring visual signal transmission to the brain. Its lead candidate RTx-015 (intravitreal, retinal ganglion cell targeting) is in a Phase 1 ENVISION trial for retinitis pigmentosa and choroideremia, and a second candidate RTx-021 (retinal ON-bipolar cell targeting) is advancing for Stargardt disease and Geographic Atrophy secondary to AMD.

Differentiator
Functional benefit
Problem solved
Product overview1 text field

Ray Therapeutics operates a single integrated optogenetics product platform rather than a multi-product software suite. The platform bioengineers and delivers light-sensitive channelrhodopsin proteins to surviving retinal neurons via AAV-based gene therapy, and is currently materialized in two named clinical-stage product candidates: RTx-015 (lead, targeting retinal ganglion cells for retinitis pigmentosa and choroideremia, in Phase 1 ENVISION trial and holding FDA RMAT and EMA PRIME designations) and RTx-021 (targeting retinal ON-bipolar cells for Stargardt Disease and Geographic Atrophy secondary to AMD, in late-stage preclinical/early clinical development). The pipeline is mutation-agnostic and intended as one-time intravitreal treatments providing lifelong vision restoration.

Product and service3 records
1RTx-015
CategoryClinical-stage optogenetic gene therapy candidate
Description

First-in-class, genotype-independent optogenetic gene therapy administered as a single intravitreal injection that bioengineers and delivers a highly light-sensitive channelrhodopsin protein (ChRown) to retinal ganglion cells, reprogramming them to act as photosensors that send visual signals to the brain. Lead indication is retinitis pigmentosa, with the Phase 1 ENVISION trial also enrolling choroideremia patients; received FDA RMAT and EMA PRIME designations in 2026.

2RTx-021
CategoryClinical-stage optogenetic gene therapy candidate
Description

Optogenetic gene therapy designed to restore vision in macular diseases such as Stargardt disease and Geographic Atrophy secondary to age-related macular degeneration (GA AMD) by targeting retinal ON-bipolar cells with a bioengineered light-sensitive protein. Late-stage preclinical/clinical-stage development supported by CIRM grants.

3Ray Therapeutics Optogenetics Platform
CategoryCore technology platform
Description

Proprietary bioengineered optogenetics platform that uses light-sensitive naturally evolved channelrhodopsin proteins to reprogram surviving retinal neurons to sense light and transmit visual signals to the brain. The platform underpins the company's mutation-agnostic, single-dose gene therapies and supports the RTx-015 and RTx-021 programs; designed to provide lifelong benefits without requiring light-enhancing eyewear.

Recent move6 records

Each record includes

Date, Type, Title, Description, Source

Expansion highlight6 records

Each record includes

Type, Description

Peers10 records
TypeBroad incumbent
Description

Clinical and commercial-stage AAV gene therapy company with multiple ophthalmology and CNS programs, including ABBV-RGX-314 for wet AMD (in-licensed to AbbVie). A larger incumbent with broad AAV platform applicability rather than a focused optogenetics niche.

TypeDirect peer
Description

Clinical-stage gene therapy company with a portfolio that includes AAV-based therapies for inherited retinal diseases (e.g., RP, achromatopsia) and other ocular indications. Closely comparable technology platform and clinical stage.

TypeDirect peer
Description

Clinical-stage biotech developing MCO-010, an ambient-light-sensitive optogenetic gene therapy for retinitis pigmentosa and Stargardt disease. Direct competitor in optogenetic retinal gene therapy, but materially further advanced (Phase 2b/3) than Ray's RTx-015.

TypeEmerging player
Description

Clinical-stage ocular therapeutics company developing sustained-release intravitreal treatments (e.g., EYP-1901 for wet AMD and diabetic macular edema) using its Durasert bioerodible technology. Comparable in intravitreal delivery and ophthalmic focus, though not a gene therapy.

TypeEmerging player
Description

Clinical-stage gene editing company developing CRISPR-based therapies including EDIT-101 for Leber congenital amaurosis 10 (LCA10). Comparable in retinal disease focus but uses gene editing rather than optogenetics.

TypeDirect peer
Description

Clinical-stage AAV gene therapy company with multiple ophthalmology programs (e.g., 4D-150 for wet AMD and diabetic macular edema) and a directed-evolution AAV platform. Ray's CMSO and CDO are former 4DMT executives, highlighting deep operational overlap.

TypeBroad incumbent
Description

Pioneering ocular gene therapy company and developer of Luxturna (voretigene neparvovec), the only FDA-approved retinal gene therapy. Now part of Roche, Spark represents the only fully validated commercial precedent for AAV retinal gene therapy.

TypeDirect peer
Description

Clinical-stage gene therapy company developing ADVM-022 (ixoberogene soroparvovec), an intravitreal AAV-based therapy for wet AMD and diabetic eye disease. Directly comparable as an intravitreal AAV gene therapy targeting retinal disease.

9SparingVision
TypeDirect peer
Description

Paris-based clinical-stage gene therapy company developing SPVN-06, a mutation-agnostic optogenetic therapy for rod-cone dystrophies including RP. Closest European peer in the optogenetic retinal space.

TypeDirect peer
Description

Clinical-stage gene therapy company developing AAV-based treatments for X-linked retinitis pigmentosa (XLRP) and other inherited retinal diseases. Closely comparable indication portfolio and AAV-delivery approach.

Market position
Strengths5 records

Each record includes

Headline, Details, Source

Weaknesses5 records

Each record includes

Headline, Details, Source

Competitive moat4 records

Each record includes

Type, Details

Key risks6 records

Each record includes

Headline, Details, Source

Key highlights6 records

Each record includes

Headline, Details, Source

Customer concentration

Classification, Details

Ideal customer profile2 records

Each record includes

Profile, Firmographic size, Sales motion, Sales cycle length, Buying structure, Purchase trigger, Buyer persona, Geography, Industry vertical, Primary use case, Description, Pain points, Evidence proof points, Target buyer

Technology focused
Yes
API detail
Has APIbool
No

Docs URL, Description

AI maturity
App detail

Has app

Feature6 records

Each record includes

Title, Differentiator, Description, Source

Core technology
Revenue estimate
Valuation estimate
Number of profiles
Profiles25 records

Each record includes

Name, Designation, Designation category, Overview, Profile commentary, Source

No data
Compliance5 records

Each record includes

Name, Class, Description

Funding overview

Funding stage, Last funding date, Total funding USD

Funding rounds7 records

Each record includes

Round, Amount USD, Date, Pre money valuation, Total investors, Investors, News

Investors13 records

Each record includes

Name, Type, Date of entry, Rounds participated, Website

Funding detail is available on the Subscription and Enterprise plan.Contact sales →

M&A

Each record includes

Name, Acquisition type, Announced date, Completed date, Status, Website, News

Investment

Each record includes

Name, Round, Announced date, Lead investor, Website, News

M&A and investment is available on the Subscription and Enterprise plan.Contact sales →

Ray Therapeutics

Ophthalmic Gene Therapy Biopharmaceuticalsraytherapeutics.com

Ray Therapeutics is a clinical-stage biotechnology company developing bioengineered optogenetic gene therapies delivered via a single intravitreal injection to restore vision in patients with blinding retinal diseases such as retinitis pigmentosa and choroideremia.

What Ray Therapeutics does

Ray Therapeutics is a clinical-stage biotechnology company founded in 2021 that develops optogenetic gene therapies intended to restore vision in patients with advanced, blinding retinal diseases. The company's core technology is a proprietary platform that uses bioengineered, highly light-sensitive channelrhodopsin proteins — notably ChRown — delivered via AAV-based gene therapy to reprogram surviving retinal neurons (ganglion cells or ON-bipolar cells, depending on the program) into functional photosensors that transmit visual signals to the brain. Because the approach is mutation-agnostic, it can in principle address retinitis pigmentosa, choroideremia, Stargardt disease, and geographic atrophy secondary to AMD through a single intravitreal injection intended as a one-time, lifelong treatment that does not require light-enhancing eyewear.

The pipeline is currently materialized in two named clinical-stage candidates: RTx-015 (lead), which targets retinal ganglion cells and is being evaluated in the ENVISION Phase 1 trial (NCT06460844) for retinitis pigmentosa and choroideremia, having received both FDA Regenerative Medicine Advanced Therapy (RMAT) designation and European Medicines Agency Priority Medicines (PRIME) designation in April 2026; and RTx-021, which targets retinal ON-bipolar cells and is being advanced for Stargardt disease and geographic atrophy (secondary to AMD).

Ray Therapeutics is pre-revenue and funds its operations through a syndicate of life-sciences venture and crossover investors and California Institute for Regenerative Medicine (CIRM) grants. Cumulative capital raised to date includes a $6M seed (2022, 4BIO Capital), a $100M Series A (2023, Novo Holdings A/S lead), a $125M Series B (2026, Janus Henderson Investors lead), and CIRM grants of $4M (2022), $4M (2023) and $8M (2025). Manufacturing is enabled through a CDMO partnership with Forge Biologics for AAV process development, scale-up, cGMP manufacturing, and plasmid DNA production. The expected go-to-market is a specialty ophthalmology commercial model leveraging one-time gene-therapy pricing typical of rare-disease retinal therapeutics, with U.S. as primary market and Europe signaled via the PRIME designation.

Ray Therapeutics firmographics

Firmographics
Name
Ray Therapeutics
Legal name
Ray Therapeutics, Inc.
Website
https://raytherapeutics.com
Company type
Private
Founded year
2021
Operating status
Operating
Headcount range
51–100 employees
Short description
Ray Therapeutics is a clinical-stage biotechnology company developing bioengineered optogenetic gene therapies delivered via a single intravitreal injection to restore vision in patients with blinding retinal diseases such as retinitis pigmentosa and choroideremia.
Ownership category
akta.pro rank

Ray Therapeutics industry classification

Industry
Product category
Ophthalmic Gene Therapy Biopharmaceuticals
NAICS
Research and Development in Biotechnology (except Nanobiotechnology) (541714)
SIC
Biological Products, (No Disgnostic Substances) (2836)
akta.pro industry
PRIMARYHLAAACAG
Ophthalmology Gene Therapies
Healthcare & Life Sciences/Biotechnology & Biologics/Gene Therapy (AAV/lentiviral/other vectors)
SECONDARYHLAAACAE
Gene Therapy for Rare/Monogenic Diseases
Healthcare & Life Sciences/Biotechnology & Biologics/Gene Therapy (AAV/lentiviral/other vectors)
SECONDARYHLAIAIAK
Rare Ophthalmology Disorder Therapies
Healthcare & Life Sciences/Pharmaceuticals/Orphan & Rare Disease Pharmaceuticals

Keywords

  • Optogenetic gene therapy
  • Retinal disease therapy
  • AAV gene therapy
  • Ophthalmic biotechnology
  • Inherited retinal diseases

Where Ray Therapeutics is headquartered

Location

Headquarters

HQ city
Berkeley
HQ country
United States
HQ region
North America

Markets served

Ray Therapeutics business model

Business model
GTM type
B2B
Offering type
Hardware or Manufacturing
Cost components
Technology or R&D, Personnel, Operations, Marketing or Sales, Supply Chain

Revenue model

  1. Pre-revenue clinical-stage gene therapy: Ray Therapeutics is a clinical-stage biopharmaceutical company with no commercial product revenue; future revenue model is expected to be one-time gene therapy treatments administered via single intravitreal injection (a unit-pricing/one-time-payment biotech model) delivered to patients with advanced retinal degeneration.
  2. Non-dilutive grant funding (CIRM): Receives milestone-based grant funding from the California Institute for Regenerative Medicine (CIRM) — including a $4M grant (CLIN2-17086) and an $8M award — supporting clinical development of optogenetic programs.
  3. Private equity financing: Capital raised via priced equity rounds: $6M seed (2022), $100M Series A (2023), $125M Series B (2026) from a syndicate of life-sciences venture and crossover investors.

Go-to-market motion3 records

Ray Therapeutics product offering

Product offering

Core offering

Ray Therapeutics is a clinical-stage biopharmaceutical company developing bioengineered optogenetic gene therapies that use light-sensitive channelrhodopsin proteins delivered via AAV-based gene therapy to reprogram surviving retinal neurons, restoring visual signal transmission to the brain. Its lead candidate RTx-015 (intravitreal, retinal ganglion cell targeting) is in a Phase 1 ENVISION trial for retinitis pigmentosa and choroideremia, and a second candidate RTx-021 (retinal ON-bipolar cell targeting) is advancing for Stargardt disease and Geographic Atrophy secondary to AMD.

Product overview

Ray Therapeutics operates a single integrated optogenetics product platform rather than a multi-product software suite. The platform bioengineers and delivers light-sensitive channelrhodopsin proteins to surviving retinal neurons via AAV-based gene therapy, and is currently materialized in two named clinical-stage product candidates: RTx-015 (lead, targeting retinal ganglion cells for retinitis pigmentosa and choroideremia, in Phase 1 ENVISION trial and holding FDA RMAT and EMA PRIME designations) and RTx-021 (targeting retinal ON-bipolar cells for Stargardt Disease and Geographic Atrophy secondary to AMD, in late-stage preclinical/early clinical development). The pipeline is mutation-agnostic and intended as one-time intravitreal treatments providing lifelong vision restoration.

Differentiator

Problem solved

Functional benefit

Brands

  • RTx-015: Lead optogenetic gene therapy candidate of Ray Therapeutics, administered as a single intravitreal injection and being evaluated in a Phase 1 clinical trial (ENVISION) for retinitis pigmentosa and choroideremia; granted FDA RMAT designation (April 2026) and EMA PRIME designation (April 2026).
  • RTx-021
  • Ray-001

Products and services

  • RTx-015 First-in-class, genotype-independent optogenetic gene therapy administered as a single intravitreal injection that bioengineers and delivers a highly light-sensitive channelrhodopsin protein (ChRown) to retinal ganglion cells, reprogramming them to act as photosensors that send visual signals to the brain. Lead indication is retinitis pigmentosa, with the Phase 1 ENVISION trial also enrolling choroideremia patients; received FDA RMAT and EMA PRIME designations in 2026.
  • RTx-021 Optogenetic gene therapy designed to restore vision in macular diseases such as Stargardt disease and Geographic Atrophy secondary to age-related macular degeneration (GA AMD) by targeting retinal ON-bipolar cells with a bioengineered light-sensitive protein. Late-stage preclinical/clinical-stage development supported by CIRM grants.
  • Ray Therapeutics Optogenetics Platform Proprietary bioengineered optogenetics platform that uses light-sensitive naturally evolved channelrhodopsin proteins to reprogram surviving retinal neurons to sense light and transmit visual signals to the brain. The platform underpins the company's mutation-agnostic, single-dose gene therapies and supports the RTx-015 and RTx-021 programs; designed to provide lifelong benefits without requiring light-enhancing eyewear.

Companies that use Ray Therapeutics

Customer profile

Ideal customer profiles2 records

Ray Therapeutics technology and API

Technology

Technology focussed Yes

API detail

Has API
No
API docs
API detail

Core technology

AI maturity

App detail

Feature6 records

Ray Therapeutics partnerships and signals

Strategic signal

Recent moves6 records

Expansion highlights6 records

Ray Therapeutics competitors and assessment

Company assessment

Broad incumbents

  • REGENXBIO: Clinical and commercial-stage AAV gene therapy company with multiple ophthalmology and CNS programs, including ABBV-RGX-314 for wet AMD (in-licensed to AbbVie). A larger incumbent with broad AAV platform applicability rather than a focused optogenetics niche.
  • Spark Therapeutics (Roche): Pioneering ocular gene therapy company and developer of Luxturna (voretigene neparvovec), the only FDA-approved retinal gene therapy. Now part of Roche, Spark represents the only fully validated commercial precedent for AAV retinal gene therapy.

Direct peers

  • MeiraGTx: Clinical-stage gene therapy company with a portfolio that includes AAV-based therapies for inherited retinal diseases (e.g., RP, achromatopsia) and other ocular indications. Closely comparable technology platform and clinical stage.
  • Nanoscope Therapeutics: Clinical-stage biotech developing MCO-010, an ambient-light-sensitive optogenetic gene therapy for retinitis pigmentosa and Stargardt disease. Direct competitor in optogenetic retinal gene therapy, but materially further advanced (Phase 2b/3) than Ray's RTx-015.
  • 4D Molecular Therapeutics: Clinical-stage AAV gene therapy company with multiple ophthalmology programs (e.g., 4D-150 for wet AMD and diabetic macular edema) and a directed-evolution AAV platform. Ray's CMSO and CDO are former 4DMT executives, highlighting deep operational overlap.
  • Adverum Biotechnologies: Clinical-stage gene therapy company developing ADVM-022 (ixoberogene soroparvovec), an intravitreal AAV-based therapy for wet AMD and diabetic eye disease. Directly comparable as an intravitreal AAV gene therapy targeting retinal disease.
  • SparingVision: Paris-based clinical-stage gene therapy company developing SPVN-06, a mutation-agnostic optogenetic therapy for rod-cone dystrophies including RP. Closest European peer in the optogenetic retinal space.
  • Beacon Therapeutics (formerly AGTC): Clinical-stage gene therapy company developing AAV-based treatments for X-linked retinitis pigmentosa (XLRP) and other inherited retinal diseases. Closely comparable indication portfolio and AAV-delivery approach.

Emerging players

  • EyePoint Pharmaceuticals: Clinical-stage ocular therapeutics company developing sustained-release intravitreal treatments (e.g., EYP-1901 for wet AMD and diabetic macular edema) using its Durasert bioerodible technology. Comparable in intravitreal delivery and ophthalmic focus, though not a gene therapy.
  • Editas Medicine: Clinical-stage gene editing company developing CRISPR-based therapies including EDIT-101 for Leber congenital amaurosis 10 (LCA10). Comparable in retinal disease focus but uses gene editing rather than optogenetics.

Market position

Strengths5 records

Weaknesses5 records

Competitive moat4 records

Key risks6 records

Key highlights6 records

Customer concentration

Ray Therapeutics social profiles

Digital presence

Ray Therapeutics compliance and trust

Trust signal

Compliance5 records

Ray Therapeutics financial estimates

Financial estimate

Revenue estimate

Valuation estimate

Ray Therapeutics leadership team

Management profile

Number of profiles

Profiles25 records

Ray Therapeutics funding detail

Funding detail

Funding overview

Funding rounds7 records

Investors13 records

Funding detail is available on the Subscription and Enterprise plan.Contact sales →

Ray Therapeutics M&A and investment

M&A and investment

M&A

Investments

M&A and investment is available on the Subscription and Enterprise plan.Contact sales →

Frequently asked questions about Ray Therapeutics

What does Ray Therapeutics do?

Ray Therapeutics is a clinical-stage biopharmaceutical company developing bioengineered optogenetic gene therapies that use light-sensitive channelrhodopsin proteins delivered via AAV-based gene therapy to reprogram surviving retinal neurons, restoring visual signal transmission to the brain. Its lead candidate RTx-015 (intravitreal, retinal ganglion cell targeting) is in a Phase 1 ENVISION trial for retinitis pigmentosa and choroideremia, and a second candidate RTx-021 (retinal ON-bipolar cell targeting) is advancing for Stargardt disease and Geographic Atrophy secondary to AMD.

Is Ray Therapeutics a public or private company?

Ray Therapeutics is a private company. It is classified as venture growth investor backed and is currently operating.

When was Ray Therapeutics founded?

Ray Therapeutics was founded in 2021. It employs 51 to 100 people.

Where is Ray Therapeutics based?

Ray Therapeutics is headquartered in Berkeley, United States, in the North America region.

How does Ray Therapeutics make money?

Three revenue lines are on record. Pre-revenue clinical-stage gene therapy is the primary driver. The others are non-dilutive grant funding (CIRM) and private equity financing.

Who are Ray Therapeutics's main competitors?

Broad incumbents on record are REGENXBIO and Spark Therapeutics (Roche). Direct peers are MeiraGTx, Nanoscope Therapeutics, 4D Molecular Therapeutics, Adverum Biotechnologies, SparingVision and Beacon Therapeutics (formerly AGTC). Emerging players are EyePoint Pharmaceuticals and Editas Medicine.

Does Ray Therapeutics have an API?

No public API is recorded for Ray Therapeutics.

What industry is Ray Therapeutics in?

Ray Therapeutics's product category is Ophthalmic Gene Therapy Biopharmaceuticals. Its primary akta.pro industry code is HLAAACAG, Ophthalmology Gene Therapies, with a secondary code of HLAAACAE, Gene Therapy for Rare/Monogenic Diseases. Its NAICS code is 541714 and its SIC code is 2836.

Unlock the full company data

50 free credits on sign-up, no credit card required.

Contact sales
Live signals
Business Wire BlogRay Therapeutics Celebrates 2026 Nobel Prize for Foundational Discoveries in OptogeneticsRay Therapeutics congratulated Drs. Karl Deisseroth, Peter Hegemann, and Georg Nagel on the 2026 Nobel Prize in Physiology or Medicine for light-gated ion channels that enabled optogenetics. The company also recognized Dr. Zhuo-Hua Pan for optogenetic vision restoration research. RayTx is advancing mutation-agnostic optogenetic gene therapies to restore vision in retinal degenerative diseases.FinSMEsRay Therapeutics Receives $8M GrantRay Therapeutics, a Berkeley-based biopharmaceutical company, received an $8M grant from the California Institute for Regenerative Medicine. The funds will advance the Phase 1/2 clinical trial and manufacturing for RTx-021, a gene therapy for Stargardt disease. The company's pipeline also includes RTx-015 for retinitis pigmentosa.FinancialContent Business PageRay Therapeutics Awarded $8 Million CIRM Grant to Advance RTx-021 Gene Therapy for Stargardt DiseaseRay Therapeutics received an $8 million CIRM grant to advance RTx-021 gene therapy for Stargardt disease. The funding supports ongoing Phase 1/2 clinical trial and manufacturing, with CIRM placing the application in its highest funding tier. The therapy aims to restore vision by enabling surviving retinal cells to respond to light.BioSpaceRay Therapeutics Awarded $8 Million CIRM Grant to Advance RTx-021 Gene Therapy for Stargardt DiseaseRay Therapeutics received an $8 million CIRM grant to advance RTx-021 for Stargardt disease. The funding supports the ongoing Phase 1/2 trial and manufacturing for late-stage development. Stargardt disease affects about 40,000 U.S. patients with no approved treatments.PR NewswireRetinitis Pigmentosa Market Outlook to Strengthen During the Forecast Period (2026-2036) with Growing Focus on Disease-Modifying Therapies | DelveInsightThe retinitis pigmentosa treatment market is expected to grow through 2036, with the US leading in 2025. Approximately 274,000 prevalent cases were diagnosed in the 7MM in 2025, and a growing pipeline of gene therapies is anticipated to broaden treatment options.pharmaphorumRay's upscaled Series B, and other biofinancingsRay Therapeutics closed a $125 million Series B to fund clinical trials of its optogenetic therapies for eye disorders. Tortugas Neuroscience raised $106 million in seed funding for four licensed drug candidates, and Serif Bio received $50 million from Flagship Pioneering. Alloy Therapeutics completed a $40 million Series E, raising its valuation above $1 billion.PrtimesWorldwide Choroideremia Treatment Market Poised to Surge at 32.65% CAGR (2026–2032) – PR TimesPW Consulting released a market study projecting the choroideremia treatment market to grow from $38.42 million in 2025 to an estimated $47.63 million in 2026, accelerating at a compound annual growth rate of 32.65% through 2032 to reach projected market levels above $270 million. The rapid expansion is driven by multiple technology approaches including gene replacement, optogenetics, and small-molecule photoswitches, alongside new regulatory designations and nonprofit-enterprise interactions, though the market remains constrained by endpoint validation challenges, high development costs, and the absence of any approved disease-modifying therapy as of 2026. Key active developers include Kiora Pharmaceuticals advancing KIO-301 in Phase 2, Ray Therapeutics with RTx-015 in Phase 1, and the Choroideremia Research Foundation following its acquisition of Spark Therapeutics' SPK-7001 assets.BioSpaceOnes to watch: 4 biotechs with recent Series B raises (that are also hiring)Four biotech companies announced Series B financing rounds in 2024–2025 and are actively recruiting as they advance their pipelines: BreezeBio ($60M), City Therapeutics ($99.5M), Neomorph ($100M), and Ray Therapeutics ($125M), totaling approximately $384.5 million across the group. BreezeBio is advancing genetic medicines including a type 1 diabetes therapy with a Genentech partnership, City Therapeutics is developing RNAi medicines for blood clots and rare eye diseases with leadership from former Alnylam executives, Neomorph is progressing molecular glue degraders for kidney cancer and solid tumors with three active Big Pharma collaborations worth up to $1.46–$1.64 billion each, and Ray Therapeutics received FDA RMAT designation for its retinitis pigmentosa candidate RTx-015 alongside its $125M raise. The article, aimed at biopharma job seekers, lists specific open positions at each company.BioSpaceRay Therapeutics Expands Board Expertise with Appointment of Vikas Sinha, MBA as Director and Chair of the Audit CommitteeRay Therapeutics appointed Vikas Sinha, MBA, to its Board of Directors and named him Chair of the Audit Committee. The appointment follows a $125 million Series B financing and FDA/EMA designations. Sinha brings over 30 years of life sciences leadership, including CFO roles at Scholar Rock and Alexion.Business Wire BlogRay Therapeutics Expands Board Expertise with Appointment of Vikas Sinha, MBA as Director and Chair of the Audit CommitteeRay Therapeutics appointed Vikas Sinha, MBA, as a director and chair of its audit committee. The appointment follows a $125 million Series B financing and FDA/EMA designations. Sinha brings over 30 years of life sciences leadership, including CFO roles at Scholar Rock and Alexion.